ArchiveJuly 2014

No Oligoclonal bands in your CSF means that you do better

Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy. Ferreira D, Voevodskaya O, Imrell K, Stawiarz L, Spulber G, Wahlund LO, Hillert J, Westman E, Karrenbauer VD. J Neuroimmunol. 2014. pii: S0165-5728(14)00181-7. doi: 10.1016/j.jneuroim.2014.06.010. [Epub ahead of print] To investigate whether multiple sclerosis (MS)...

Mice work may send you down the wrong path becuase of the mouse you use

Kraev A. Parallel universes of Black Six biology. Biol Direct. 2014 Jul 19;9(1):18 Creation of lethal and synthetic lethal mutations in an experimental organism is a cornerstone of genetic dissection of gene function, and is related to the concept of an essential gene. Common inbred mouse strains carry background mutations, which can act as genetic modifiers, interfering with the assignment of...

Progression is this an easy mountain to CLIMB

Raghavan K, Healy BC, Carruthers RL, Chitnis T. Progression rates and sample size estimates for PPMS based on the CLIMB study population. Mult Scler. 2014 Jul. pii: 1352458514541976. [Epub ahead of print] BACKGROUND: The clinical trial design for primary progressive multiple sclerosis (PPMS) requires understanding of disability progression in modern patient cohorts...

PLEG RIDY arrives in Europe

It has been announced that the European Regulators have approved Plegridy for MS. Plegridy is an interferon drug, the same type of treatment as Biogen Idec’s first multiple sclerosis therapy, Avonex. While Avonex typically is injected into the muscle once a week, Plegridy can be taken by injection once every two weeks and administered under the skin with a prefilled auto-injector.  This is a...

Employment in MSers (Norway)

Bøe Lunde HM, Telstad W, Grytten N, Kyte L, Aarseth J, Myhr KM, Bø L. Employment among Patients with Multiple Sclerosis-A Population Study. PLoS One. 2014 ;9(7):e103317. doi: 10.1371/journal.pone.0103317. eCollection 2014.OBJECTIVE:To investigate demographic and clinical factors associated with employment in MS. METHODS: The study included 213 (89.9%) of all MS patients in Sogn and...

MS on the up globally

Melcon MO, Correale J, Melcon CM. Is it time for a new global classification of multiple sclerosis? J Neurol Sci. 2014 Jun 29. pii: S0022-510X(14)00421-3 BACKGROUND: The geographic distribution of multiple sclerosis (MS) is classically divided into three zones based on frequency that were established by Kurtzke in the early 1970s. In recent years, an increasing number of...

Clearing up debris to help repair

Rajbhandari L, Tegenge MA, Shrestha S, Ganesh Kumar N, Malik A, Mithal A, Hosmane S, Venkatesan A. Toll-like receptor 4 deficiency impairs microglial phagocytosis of degenerating axons.Glia. 2014 Jul 8. doi: 10.1002/glia.22719. [Epub ahead of print] Microglia are rapidly activated in the central nervous system (CNS) in response to a variety of injuries, including inflammation, trauma, and...

lentiviral anti-lingo supports remyelination

Wang CJ, Qu CQ, Zhang J, Fu PC, Guo SG, Tang RH. Lingo-1 Inhibited by RNA Interference Promotes Functional Recovery of Experimental Autoimmune Encephalomyelitis. Anat Rec (Hoboken). 2014 Jul . doi: 10.1002/ar.22988. [Epub ahead of print] Lingo-1 is a negative regulator of myelination. Repairment of demyelinating diseases, such as multiple sclerosis (MS)/experimental autoimmune...

Low-dose naltrexone for treatment of multiple sclerosis Are clinical trials needed. Will they happen?

Every time I talk about complementary/alternative medicine to MSers someone tells me of a good luck story about low dose naltrexone. Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence. Naltrexone should not be confused with naloxone (which is used in emergency cases of opioid overdose) nor nalorphine. Using naloxone in place of...

Neural network disruption

Tewarie P, Steenwijk MD, Tijms BM, Daams M, Balk LJ, Stam CJ, Uitdehaag BM, Polman CH, Geurts JJ, Barkhof F, Pouwels PJ, Vrenken H, Hillebrand A.Disruption of structural and functional networks in long-standing multiple sclerosis. Hum Brain Mapp. 2014 Jul 22. doi: 10.1002/hbm.22596. [Epub ahead of print] Both gray matter atrophy and disruption of functional networks are important predictors...

Translate

Categories

Recent Posts

Recent Comments

Archives